Geode Capital Management’s Seelos Therapeutics, Inc. Common Stock SEEL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-800
| Closed | -$7.64K | – | 4595 |
|
|
2024
Q2 | $7.64K | Hold |
800
| – | – | ﹤0.01% | 4556 |
|
|
2024
Q1 | $60.5K | Buy |
800
+571
| +249% | +$75.3K | ﹤0.01% | 4282 |
|
|
2023
Q4 | $40.8K | Sell |
229
-87
| -28% | -$42.8K | ﹤0.01% | 4401 |
|
|
2023
Q3 | $223K | Buy |
316
+12
| +4% | +$51.5K | ﹤0.01% | 3939 |
|
|
2023
Q2 | $1.39M | Buy |
304
+8
| +3% | +$27.8K | ﹤0.01% | 3231 |
|
|
2023
Q1 | $787K | Buy |
296
+5
| +2% | +$14.6K | ﹤0.01% | 3453 |
|
|
2022
Q4 | $757K | Buy |
291
+3
| +1% | +$10.5K | ﹤0.01% | 3488 |
|
|
2022
Q3 | $1.14M | Buy |
288
+27
| +10% | +$106K | ﹤0.01% | 3328 |
|
|
2022
Q2 | $681K | Sell |
261
-160
| -38% | -$417K | ﹤0.01% | 3588 |
|
|
2022
Q1 | $1.35M | Buy |
421
+8
| +2% | +$34.4K | ﹤0.01% | 3471 |
|
|
2021
Q4 | $2.58M | Sell |
413
-35
| -8% | -$269K | ﹤0.01% | 3254 |
|
|
2021
Q3 | $4.15M | Buy |
448
+94
| +27% | +$808K | ﹤0.01% | 3019 |
|
|
2021
Q2 | $3.59M | Buy |
354
+213
| +151% | +$3.5M | ﹤0.01% | 3091 |
|
|
2021
Q1 | $2.71M | Buy |
141
+60
| +74% | +$700K | ﹤0.01% | 3110 |
|
|
2020
Q4 | $492K | Buy |
81
+41
| +103% | +$161K | ﹤0.01% | 3597 |
|
|
2020
Q3 | $144K | Hold |
40
| – | – | ﹤0.01% | 3820 |
|
|
2020
Q2 | $155K | Hold |
40
| – | – | ﹤0.01% | 3734 |
|
|
2020
Q1 | $75K | Hold |
40
| – | – | ﹤0.01% | 3845 |
|
|
2019
Q4 | $206K | Hold |
40
| – | – | ﹤0.01% | 3785 |
|
|
2019
Q3 | $141K | Hold |
40
| – | – | ﹤0.01% | 3877 |
|
|
2019
Q2 | $336K | Buy |
40
+30
| +300% | +$316K | ﹤0.01% | 3606 |
|
|
2019
Q1 | $129K | Buy |
10
+8
| +400% | +$129K | ﹤0.01% | 3842 |
|
|
2018
Q4 | $43K | Hold |
2
| – | – | ﹤0.01% | 4016 |
|
|
2018
Q3 | $70K | Hold |
2
| – | – | ﹤0.01% | 3986 |
|
|
2018
Q2 | $89K | Buy |
+2
| New | +$75.3K | ﹤0.01% | 3892 |
|
|
2018
Q1 | – | Hold |
0
| – | – | – | 4035 |
|
|
2017
Q4 | – | Hold |
0
| – | – | – | 3937 |
|
|
2017
Q3 | – | Hold |
0
| – | – | – | 3957 |
|
|
2017
Q2 | – | Hold |
0
| – | – | – | 4021 |
|
|
2017
Q1 | – | Hold |
0
| – | – | – | 3938 |
|
|
2016
Q4 | – | Hold |
0
| – | – | – | 3962 |
|
|
2016
Q3 | – | Hold |
0
| – | – | – | 3835 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 3799 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 3717 |
|
|
2015
Q4 | – | Hold |
0
| – | – | – | 3590 |
|
|
2015
Q3 | – | Hold |
0
| – | – | – | 3366 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 3253 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 3220 |
|
|
2014
Q4 | – | Hold |
0
| – | – | – | 3641 |
|
|
2014
Q3 | – | Hold |
0
| – | – | – | 3589 |
|
|
2014
Q2 | – | Hold |
0
| – | – | – | 3401 |
|
|
2014
Q1 | – | Hold |
0
| – | – | – | 3396 |
|
|
2013
Q4 | – | Hold |
0
| – | – | – | 3249 |
|
|
2013
Q3 | – | Hold |
0
| – | – | – | 3206 |
|
|
2013
Q2 | – | Hold |
0
| – | – | – | 3092 |
|
Other funds holding SEEL
AI
MWM
TRCT
CHA
Geode Capital Management's SEEL Position: Q3 2024 in Review
Geode Capital Management sold out of Seelos Therapeutics, Inc. Common Stock (SEEL) in Q3 2024, closing a stake of 800 shares — an estimated $7.64K sold.
Geode Capital Management first reported a position in SEEL in Q2 2018 and held it in 25 quarters. The position peaked at $4.15M in Q3 2021. 15 funds tracked by Wall St. Rank hold SEEL as of Q3 2024.
- Geode Capital Management reported no remaining Seelos Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Geode Capital Management sold 800 Seelos Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $7.64K.
- Geode Capital Management first reported a position in Seelos Therapeutics, Inc. Common Stock in Q2 2018 and held it in 25 quarters.
- Geode Capital Management's Seelos Therapeutics, Inc. Common Stock position peaked at $4.15M in Q3 2021.
- 15 funds tracked by Wall St. Rank held Seelos Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Geode Capital Management's 13F filing for Q3 2024, filed 12 Nov 2024.